| Anti-B cell maturation antigen chimeric antigen receptor T cell therapy for the treatment of AL amyloidosis and concurrent relapsed/refractory multiple myeloma: preliminary … S Das, S Ailawadhi, T Sher, V Roy, A Fernandez, RD Parrondo Current Oncology 30 (11), 9627-9633, 2023 | 8 | 2023 |
| Factors determining utilization of stem cell transplant for initial therapy of multiple myeloma by patient race: exploring intra-racial healthcare disparities S Ailawadhi, Y Adu, RD Frank, S Das, DO Hodge, A Fernandez, C Flott, ... Blood Cancer Journal 14 (1), 86, 2024 | 4 | 2024 |
| Patient Awareness of CAR-T and Bispecific Antibody Treatments for Multiple Myeloma: Real-World Learnings and Disparities Y Adu, S Das, D Ailawadhi, A Fernandez, R Parrondo, V Roy, T Sher, ... Blood 142, 2418, 2023 | 2 | 2023 |
| Phase II trial of elotuzumab with pomalidomide and dexamethasone for daratumumab-refractory multiple myeloma RD Parrondo, BR LaPlant, J Elliott, A Fernandez, CJ Flott, D Arrington, ... Blood cancer journal 14 (1), 152, 2024 | 1 | 2024 |
| The digital divide: Racial disparities in adoption and utilization of health information technology among patients with lymphoid cancers Ailawadhi, S., Ailawadhi, M., Dutta, N., Parrondo, R. D., Roy, V., Sher, T ... Cancer Medicine, 2023 | 1 | 2023 |
| AML-286: Intentional Azole Antifungals with Azacitidine-Venetoclax Based Combination in AML as an Outpatient Therapy: Experience from a Resource-Limited Setting in India AK Baa, RK Sahoo, S Chitikela, S Das, L Kumar Clinical Lymphoma Myeloma and Leukemia 21, S300-S301, 2021 | 1 | 2021 |
| Real World Outcomes with Venetoclax (Ven)-Based Therapies in Patients with Heavily Pretreated Relapsed/Refractory Multiple Myeloma (RRMM): A Mayo Clinic Comprehensive Cancer … RD Parrondo, S Das, H Sledge, A Bolarinwa, J Elliott, A Fernandez, ... Blood 144, 1981, 2024 | | 2024 |
| Awareness Regarding Clinical Trials Among Patients with Multiple Myeloma (MM): A Systematic Study to Validate Online Platforms for Conducting Patient Surveys JR Hydren, MS Barnes, RM Jensen, L Bojanini, D Ailawadhi, S Das, ... Blood 144, 7620, 2024 | | 2024 |
| Survivorship Burden and Patient Preferences Affecting Treatment Choices Among Multiple Myeloma (MM) Patients: Real-World Learnings from a Large, Prospective Study J Mondy, S Das, D Ailawadhi, Y Adu, S Ailawadhi Blood 144, 3771, 2024 | | 2024 |
| P-412 Real World Outcomes with Elotuzumab-Based Therapies for Patients with Relapsed Refractory Multiple Myeloma (RRMM): A Mayo Clinic Experience R Parrondo, S Das, D Hodge, H Sledge, PL Bergsagel, R Fonseca, ... Clinical Lymphoma Myeloma and Leukemia 24, S272-S273, 2024 | | 2024 |
| A phase II study of ibrutinib in combination with ixazomib in patients with Waldenström macroglobulinaemia RD Parrondo, N Dutta, BR LaPlant, J Elliott, A Fernandez, A Zimmerman, ... British journal of haematology 204 (5), 1825-1829, 2024 | | 2024 |
| LOT-CRT in patients with refractory heart failure and non-LBBB morphology: A case series D Kumar, S Das, R Chakraborty, SS Mukherjee, D Mondal, PP Das Heart Failure Journal of India 1 (2), 158-162, 2023 | | 2023 |
| Poster: AML-248: Clinico-Pathological Profile of Therapy-Related Acute Myeloid Leukemia S Gajendra, S Das, R Chadha, B Jha, S Goel, A Yadav, T Sahni, ... Clinical Lymphoma Myeloma and Leukemia 21, S214, 2021 | | 2021 |
| AML-248: Clinico-Pathological Profile of Therapy-Related Acute Myeloid Leukemia S Gajendra, S Das, R Chadha, B Jha, S Goel, A Yadav, T Sahni, ... Clinical Lymphoma Myeloma and Leukemia 21, S295, 2021 | | 2021 |
| Poster: AML-286: Intentional Azole Antifungals with Azacitidine-Venetoclax Based Combination in AML as an Outpatient Therapy: Experience from a Resource-Limited Setting in India AK Baa, RK Sahoo, S Chitikela, S Das, L Kumar Clinical Lymphoma Myeloma and Leukemia 21, S216, 2021 | | 2021 |
